Molecular Pathology Tests: Choosing Among the Many Jennifer Laudadio, MD University of Arkansas for Medical Sciences.

Slides:



Advertisements
Similar presentations
Consolidated User Story 1: Chronic Diseases (cancer, occupational health) Chronic Diseases, Outpatient Flow Patient, Provider/Physician, Laboratory, PH.
Advertisements

Regulation of Consumer Tests in California AAAS Meeting June 1-2, 2009 Beatrice OKeefe Acting Chief, Laboratory Field Services California Department of.
+ HEALTH INSURANCE: UNDERSTANDING YOUR COVERAGE Navigator Name Blank County Extension UGA Health Navigators.
Cell block: Monokeratin – rare dot Tissue biopsy: Monokeratin – positive On Slide Control.
…and that the right diagnosis is critical to your patients’ outcomes. UW Ocular Pathology Laboratory Because you know ocular tissue is different …
Disclosure/Communication of Laboratory Errors Raouf E Nakhleh, MD Mayo Clinic Florida.
Foundation.cap.org v. # Consultations in Pathology Practice: Clinicians & Patients Jennifer L. Hunt, MD, MEd Associate Chief of Pathology Massachusetts.
REYNOLDS POLLOCK & ASSOCIATES EXPERIENCE | INSIGHT | STRATEGY Reimbursement for Molecular Diagnostics Michael Pollock SLA Annual Conference June 11, 2013.
EGFR Mutation Testing From the Pathologist’s Point of View
Molecular Testing of lung cancer in routine practice
KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.
EGFR gene mutation testing in NSCLC
Procedures used by CHTN
Frequently Asked Questions. No, in fact DOCTUS considers itself a strategic extension of your organization. Hence, we deliver the work the way you do.
Molecular profiling of colorectal cancers
Moving Toward Personalized Treatment for Gastric Cancer: Role of HER2 Testing Frédérique Penault-Llorca, MD, PhD Professor of Pathology Centre Jean Perrin.
Kenneth Sisco, MD, PhD, FCAP Medical Director Quest Diagnostics
Ian Jaffee, MD FCAP Director of Cytopathology
HealthTranz Payment Solutions Total Payment Solutions for Healthcare Practices.
About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.
Melanoma Focus Meeting 2012 Mutation Testing: Why, When, Which and How?
Chapter 10 Molecular Diagnosis. Keypoints Identification of the gene for a disorder permits diagnostic testing by direct mutation analysis. Some genetic.
Stan Hamilton, MD Professor and Head Pathology and Laboratory Medicine
Member Mail Order Helpful Hints, Reminders and Tools.
About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.
Implementing universal Lynch Syndrome screening in a large healthcare system.
Adult-Onset Disease The Example of Colon Cancer Summer, 2012.
Data Analysis Summary. Elephant in the room General Comments General understanding that informatics is integral in medical sequencing and other –omics.
NCI Workshop Bethesda, MD May 3 – 4, 2012 Next-Generation DNA Sequencing as a Tool for Clinical Decision-making in Cancer Patient Management.
About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
CUG Request from 2010 and 2011 User Group Meetings Cortex User Group Meeting Portland, OR – 2012.
Pathology Reports Nicole Draper, MD.
Development of Molecular Methodologies for the Enhanced Detection of Tumour Biomarkers Michelle Wood, Hood Mugalassi, Justyna Tull, Linda Meredith, Rachel.
Upon completion of this lesson, you will be able to: Identify different diagnostic procedures for breast cancer screening Describe different diagnostic.
An Equal Opportunity University University Health Service We are here for you!
The UWCCC/WON Molecular Tumor Board (MTB) & Registration Protocol Mark E. Burkard MD PhD WON fall meeting October 24, 2015.
Module Three: Identifying your Patient in SIS. Introduction – Search for 1 st T Specimen The Search for 1 st T Specimen screen is used to access your.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Mammography Regulations and Standards in the U.S.: The Basics of the Mammography Quality Standards Act Helen J. Barr, MD Director, Division of Mammography.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,
R2 김재민 / Prof. 정재헌 Journal conference 1.
1 Regulatory And Cost Containment Issues Affecting Molecular Diagnostics Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology.
Managing Colon cancer in the era of molecular markers
BREAST CANCER ONCOLOGY NAVIGATION SERVICE
Coordination (benign lesions)
Improved diagnosis, therapy and outcomes for patients with CUP
The introduction of NGS panel tests in the Belgian healthcare system
Approximately 85% of lung cancers are classified as non-small cell lung cancer (NSCLC); of these, adenocarcinoma accounts for 50% of cases, and squamous.
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors  Rajyalakshmi.
Tissue Acquisition and Reflex Testing How do we Prioritize?
Applying Genomic Profiling to Precision Cancer Medicine in Clinical Practice George D. Demetri MD Senior Vice-President for Experimental Therapeutics.
Mark G. Erlander, Xiao-Jun Ma, Nicole C
KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal Cancers  Katharina Balschun, Jochen Haag, Ann-Kathrin.
Tissue acquisition and reflex testing. How do we prioritize?
Handling and Evaluation of Breast Cancer Biopsy
2015 Medicare Payment Changes
Coverage and Reimbursement to Genetic Testing
Ashleigh C. McEvoy, Benjamin A. Wood, Nima M. Ardakani, Michelle R
A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer  Yasushi Yatabe, Toyoaki Hida, Yoshitsugu Horio, Takayuki.
A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non–Small-Cell Lung Cancer (NSCLC) Bronchoscopy.
Validation and Reproducibility of a Microarray-Based Gene Expression Test for Tumor Identification in Formalin-Fixed, Paraffin-Embedded Specimens  Raji.
Talk outline Brief history of gene-expression profiling for cancer type classification Current commercially available tests - development and performance.
Isabel C. Scarinci, PhD, MPH James Kendrick, MD Edward Partridge, MD
Next-Generation Sequencing and ctDNA
UPDATEs IN GASTROINTESTINAL PATHOLOGY
New Provider and Reappointment Training
Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis  Paolo A. Ascierto, Carlo Bifulco, Giuseppe.
Presentation transcript:

Molecular Pathology Tests: Choosing Among the Many Jennifer Laudadio, MD University of Arkansas for Medical Sciences

Disclosures None

Objectives Assess appropriateness of molecular testing requests and decide among the available methods Evaluate quality and cost-effectiveness of testing options when deciding which ones to bring in-house

THE 3PM PHONE CALL (OR )

What Now? The test you know absolutely nothing about The test you know about but don’t know if the methodology matters and don’t know where to send it The test you know all about but don’t know where to send it The test request you know how to handle – EASY, DONE

The test you know nothing about Spend a couple of hours researching the test Knock on your colleagues door Ask your colleague requesting the test to send you information Check reference lab test menus Check test menuwww.amp.org

The test you know nothing about Is this medically necessary? What is the cost? Has the requesting doctor talked to the patient about this super expensive test? Do multiple labs offer the test? Do all labs use the same test method?

Example “That test that tells me where the primary tumor is”

What tests are available? Biotheranostics Pathwork Diagnostics Rosetta Genomics

Biotheranostics CancerType ID Laser micro-dissection (need special slides) Real Time RT-PCR 92 genes 87 tumor associated 5 reference Classifies 50 cancer types/subtypes 87% accurate for 28 main tumor types 82% accurate for 50 subtypes

Pathwork Diagnostics Tissue of Origin Test DNA based expression array ~2000 genes Classifies 15 primary types/ 58 morphologies 89% positive agreement FDA-cleared for formalin fixed paraffin embedded tissue

Rosetta Genomics miRview Mets 2 Expression levels of micro-RNAs 64 micro-RNAs Classifies 42 tumor types 85% sensitivity

What tissue is available for testing? What are the specimen requirements for each test? Specimen size? Tumor cellularity? Decalcified? Test methodology can impact what sample is acceptable.

Is each test equally “good”? Monzon FA and Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med. 2010; 134(2):

Shipping Requirements? Don’t forget about the $$! Does the company direct patient/insurance bill? What is the cost of the test? Has the oncologist discussed this test with the patient?

The test you know nothing about Yes, there will be preliminary information gathering necessary – Ask the requesting oncologist for information – Ask your colleagues if they have had any experience with any of the tests and what they thought Yes, the second time you get this request, it will go much smoother

The test you have heard about Method? – Probably the hardest part – Intro to molecular methods CME – Webinars Which reference lab? Specimen requirements? – Test the primary or metastasis?

Example KRAS mutation testing for metastatic colorectal carcinoma

Methodology Sensitivity Specific codons targeted by the method Examples of methods used for KRAS testing – Sequencing – Pyrosequencing – Allele specific PCR

KRAS Methodology Sequencing – Get information on entire exon – Need at least 20% mutant allele – Does lab inhibit wild type alleles to increase sensitivity? Pyrosequencing – Improves sensitivity – Targets specific mutations – Special instrumentation Allele specific PCR – Targets specific codon 12 and 13 point mutations – Sensitivity down to ~1% mutant allele – Is it too sensitive?

Specimen Requirements and Selecting a Reference Lab FFPE acceptable – Block – Unstained slides (don’t have to be charged) Test either the metastasis or primary The usual reference lab – all our reference testing has to go to lab X Search for a reference lab – Google reference lab test menus Mayo Test Menu – Get info on methodology, specimen requirements, clinical utility, access requisition form, etc

Scenarios have been reactive What about being proactive?

Proactive You make that phone call to recommend a test Reflex testing policy

You recommend a test You diagnose metastatic colorectal carcinoma in a liver biopsy – call surgeon or oncologist and ask if they want it sent for KRAS testing.

Reflex Testing HPV for oropharyngeal squamous cell carcinomas

Establishing a Reflex Testing Policy Communication – Requests from clinicians – Agreement among Pathologists Methodology How to get a reflex testing policy approved? – Medical Center Dependent – How to communicate the new policy once approved Monitor adherence

Specifics from experience with HPV Multi-disciplinary requests ENT surgeons Medical oncologist Radiation oncologist Indications Prognostic and Predictive Diagnostic

Specifics from experience with HPV Choosing a Methodology – In situ hybridization High specificity Low sensitivity – PCR High sensitivity Is it too sensitive? – P16 Surrogate High sensitivity Lower specificity In situ hybridization p16 IHC

Specifics from experience with HPV Drafting a Reflex Policy – Specific Diagnoses that would trigger the reflex test – CPT codes Getting the Policy Approved Communicating the Policy

You want to get into the Molecular Diagnostics Game What tests to bring in house?

Test Volumes If you build it, will they come? Cost savings?

Type of equipment and expertise needed? FDA approved tests Require less expertise Expense Verification of performance characteristics Lab Developed tests Time for development Expertise More rigorous validation

What’s Realistic Dedicated Research/Development person One test a month Pathologists also involved in patient care 3-4 tests per year Don’t forget the need for IT support!!

Will I get paid? New CPT codes Based on analyte being tested Not method specific Replace “stacking” codes On clinical lab fee schedule G code for professional interpretation Gap-fill method of determining reimbursement Critical time to work with payers

Take Home Points Yes, it can be taxing to your practice to evaluate molecular testing requests. You can handle these requests either proactively or reactively Reactive is not necessarily bad Take advantage of the resources around you – the requesting MD, other pathologists, On-line test menus, Google, webinars, CME

Take Home Points: Examples of Tests Tests for tumor of unknown origin – Medical necessity – Methodology and Targeted genes – Specimen Requirements KRAS – Methodology and Mutation targets – Finding a reference lab – Mets versus Primary HPV – Developing a reflex testing policy – Selecting a method

Take Home Points A basic understanding of molecular techniques may prove useful Deciding to bring tests in-house – FDA-approved versus lab developed – Performance Characteristics – Cost – Expertise necessary

Thank You